Data / Drug companies / Xellia Pharmaceuticals USA LLC
Xellia Pharmaceuticals USA LLC: 36 products in the FDA NDC directory, labeler code 70594
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Xellia Pharmaceuticals USA LLC (labeler code 70594) lists 36 products in the FDA National Drug Code Directory, covering 13 finished drugs by generic name. By type: 36 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 3, 2023.
The request: Watch Xellia Pharmaceuticals USA LLC (FDA labeler code 70594): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70594
- Products in commercial distribution
- 36
- Packages
- 42
- Finished drugs by generic name
- 13
- Prescription products
- 36
- Over the counter products
- 0
- Flagged as original packager
- 36 of 36 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- February 23, 2016
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 25 | 69.4% |
| New drug applications (NDA) | 11 | 30.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 36 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Bupivacaine hydrochloride | 8 | 23 |
| Vancomycin | 7 | 2 |
| Daptomycin | 5 | 25 |
| Phenylephrine hydrochloride | 3 | 77 |
| Colistimethate sodium | 2 | 4 |
| Neostigmine methylsulfate | 2 | 24 |
| Meropenem | 2 | 17 |
| Vancomycin hydrochloride | 2 | 39 |
| Voriconazole | 1 | 34 |
| Carboprost tromethamine | 1 | 22 |
| Polymyxin b sulfate | 1 | 6 |
| Sumatriptan succinate | 1 | 24 |
| Acetylcysteine | 1 | 15 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 16 | 44.4% |
| Injection, powder, lyophilized, for solution | 8 | 22.2% |
| Injection | 6 | 16.7% |
| Injection, powder, for solution | 5 | 13.9% |
| Solution | 1 | 2.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Daptomycin | 70594-066 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | November 3, 2023 |
| Daptomycin | 70594-060 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | November 3, 2023 |
| Carboprost Tromethamine | 70594-112 | Solution | Generic drugs (ANDA) | November 1, 2023 |
| Voriconazole | 70594-067 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | August 24, 2023 |
| Bupivacaine HCl | 70594-119 | Injection, solution | Generic drugs (ANDA) | August 1, 2023 |
| Bupivacaine HCl | 70594-116 | Injection, solution | Generic drugs (ANDA) | August 1, 2023 |
| Acetylcysteine | 70594-111 | Injection, solution | Generic drugs (ANDA) | June 10, 2023 |
| Bupivacine HCl | 70594-121 | Injection, solution | Generic drugs (ANDA) | June 1, 2023 |
| Bupivacaine HCl | 70594-120 | Injection, solution | Generic drugs (ANDA) | June 1, 2023 |
| Bupivacaine HCl | 70594-118 | Injection, solution | Generic drugs (ANDA) | June 1, 2023 |
| Bupivacaine HCl | 70594-117 | Injection, solution | Generic drugs (ANDA) | June 1, 2023 |
| BUPIVACAINE HCl | 70594-115 | Injection, solution | Generic drugs (ANDA) | June 1, 2023 |
| Bupivacaine HCl | 70594-114 | Injection, solution | Generic drugs (ANDA) | June 1, 2023 |
| Colistimethate | 70594-023 | Injection, powder, for solution | Generic drugs (ANDA) | February 20, 2022 |
| Sumatriptan | 70594-068 | Injection | Generic drugs (ANDA) | January 1, 2022 |
| Phenylephrine Hydrochloride | 70594-065 | Injection | Generic drugs (ANDA) | January 1, 2022 |
| Phenylephrine Hydrochloride | 70594-064 | Injection | Generic drugs (ANDA) | January 1, 2022 |
| Phenylephrine Hydrochloride | 70594-063 | Injection | Generic drugs (ANDA) | January 1, 2022 |
| Meropenem | 70594-076 | Injection, powder, for solution | Generic drugs (ANDA) | June 28, 2021 |
| Meropenem | 70594-075 | Injection, powder, for solution | Generic drugs (ANDA) | June 28, 2021 |
| Daptomycin | 70594-034 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 1, 2021 |
| Neostigmine Methylsulfate | 70594-072 | Injection | Generic drugs (ANDA) | January 10, 2021 |
| Neostigmine Methylsulfate | 70594-069 | Injection | Generic drugs (ANDA) | January 10, 2021 |
| Vancomycin | 70594-058 | Injection, solution | New drug applications (NDA) | May 13, 2020 |
| Vancomycin | 70594-056 | Injection, solution | New drug applications (NDA) | May 13, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.